{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:00:00Z","timestamp":1791968400750,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a chronic, fluctuating disease whose unique natural history complicates designing therapeutic trials. The evidence on which many MG management recommendations are based is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the degree of knowledge, agreement, and application of internationally recognized recommendations for managing MG in actual practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A cross-sectional survey was conducted among Spanish neurologists specializing in MG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The survey assessed knowledge, agreement, and application of recommendations, along with the degree of agreement with international consensus definitions from the Myasthenia Gravis Foundation of America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-three neurologists (mean age 45.4\u2009years, 53% men) attended an average of 3.6 patients with MG daily. In 40 out of 61 recommendations, at least 90% of the neurologists were aware of the recommendation. The least known recommendations dealt with juvenile MG and MG in pregnancy. There was no majority agreement in two recommendations (for MG in pregnancy and the use of intravenous immunoglobulin in mild or ocular MG). The implementation of the recommendations was high except for the ones related to plasma exchange, thymectomy, methotrexate, or eculizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The recommendations are well-known, agreed upon, and applied. However, the evidence, consensus, and knowledge dissemination need reinforcement regarding aspects such as the management of juvenile MG, MG in pregnancy, or the use of certain treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406223251368063","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T10:01:58Z","timestamp":1757584918000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Practitioner\u2019s perception of myasthenia gravis management recommendations in clinical practice: a cross-sectional survey study"],"prefix":"10.1177","volume":"16","author":[{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"first","affiliation":[{"name":"Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"},{"name":"Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Guerrero-Sola","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Caballero-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Campos-Lucas","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-7730","authenticated-orcid":false,"given":"Juan","family":"G\u00f3mez-Salgado","sequence":"additional","affiliation":[{"name":"Department of Sociology, Social Work and Public Health, Faculty of Labour Sciences, University of Huelva, Avda. Tres de Marzo, S\/N, Huelva 21007, Spain"},{"name":"Safety and Health Postgraduate Programme, Universidad Esp\u00edritu Santo, Guayaquil, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Monge-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"\u00c1lvarez-Velasco","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"3","key":"e_1_3_4_2_2","first-page":"119","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez DA","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J. Myasthenia gravis. Update on diagnosis and therapy. Med Clin 2023; 161(3): 119\u2013127.","journal-title":"Med Clin"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03185-7"},{"issue":"2","key":"e_1_3_4_7_2","first-page":"59","article-title":"[Epidemiology of myasthenia gravis in the Iberian Peninsula and Latin America]","volume":"76","author":"Garc\u00eda-Est\u00e9vez DA","year":"2023","unstructured":"Garc\u00eda-Est\u00e9vez DA, Fraga-Bau A, Garc\u00eda-Sobrino T, et al. [Epidemiology of myasthenia gravis in the Iberian Peninsula and Latin America]. Rev Neurol 2023; 76(2): 59\u201368.","journal-title":"Rev Neurol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001196"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"e_1_3_4_12_2","unstructured":"Euro Myasthenia. Myasthenia gravis: clinical guidelines [Internet] https:\/\/www.myastheniagravis.cz\/images\/guidelines-euromyasthenia.pdf (2020 accessed 31 March 2024)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596382"},{"key":"e_1_3_4_14_2","unstructured":"Myastenia Gravis Foundation of America. MGFA-PIS [Internet] https:\/\/myasthenia.org\/Portals\/0\/MGFA%20-%20PIS.pdf (2023 accessed 28 November 2023)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27064"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2017.04.003"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.01.004"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2178302"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00743"},{"key":"e_1_3_4_20_2","unstructured":"AEMPS. Ciclosporina. Ficha t\u00e9cnica [Internet] https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/60320\/FT_60320.html (2023 accessed 29 Nov 2023)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15414"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2015.4121"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5178-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S333501"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P5.9-077"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205280"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.07.037"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170284"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfn041"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.01967.x"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.7875"},{"key":"e_1_3_4_33_2","unstructured":"EMA. Efgartigimod. Summary of product characteristics [Internet] https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf (2022 accessed 29 November 2023)."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1229112"},{"key":"e_1_3_4_35_2","unstructured":"U.S. Food and Drug Administration. Ultomiris (ravulizumab). Highlights of prescribing information [Internet] https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf (2022 accessed 30 March 2024)."}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251368063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223251368063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251368063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:20:14Z","timestamp":1777591214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223251368063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"alternative-id":["10.1177\/20406223251368063"],"URL":"https:\/\/doi.org\/10.1177\/20406223251368063","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"20406223251368063"}}